1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. PROCESSA PHARMACEUTICALS INC
Processa Pharmaceuticals Inc
XNAS: PCSA
Download real time
1.84-0.12(-6.12%)
87.09% Fall from 52W High
16,224
XNAS Volume

XNAS 21 Sep, 2026 5:30 PM (EDT)

Portfolio

Alert

My Notes

Processa Pharma Inc quarterly and annual earnings report: results, revenue, profit, P&L, balance sheet, cash flow, financial ratios, revenue mix, peer comparison, and financial documents

View Charts

Processa Pharma Inc quarterly results: revenue, profit, and P&L – 13 quarter history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
Nested row level
Base Level
Export
  • NEUTRAL

    Quarterly Revenue Processa Pharma Inc Jun-2026 Quarterly Revenue is $0 Million which is growth of 0% YoY.

  • POSITIVE

    Quarterly Net Profit Processa Pharma Inc Jun-2026 Quarterly Net Profit is $-3 Million which is growth of 17.0% YoY.

Processa Pharmaceuticals Inc, Earnings Report - Quarterly Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphJun '26Mar '26Dec '25Sep '25Jun '25Mar '25Dec '24Sep '24Jun '24Mar '24Dec '23Sep '23Jun '23
Operating Rev.
Cost Of Rev.
-------------
Gross Profit
-------------
⌄
2.33.33.73.542.92.73.43.12.82.52.22.7
Operating Profit
-2.3-3.3-3.7-3.5-4-2.9-2.7-3.4-3.1-2.8-2.5-2.2-2.7
⌄
000.1-000-0.10.10.10.1
Profit Before Tax
-3.3-3.4-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Tax
----------
⌄
-3.3-3.4-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Diluted NI Avail to Com Stockholders Ann.
-3.3-3.4-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Basic EPS
-1.2-1.3-1.3-1.8-6.3-7.5-18.5-25.8-25.3-27.8-46.8-40-50
Diluted EPS After ExtraOrdinary
-0.9-1.3-1.3-1.8-6.3-7.5-18.5-25.8-25.3-27.8-46.8-40-50
Number Of Shares End
2.82.62.61.90.60.40.10.10.10.10.10.10.1
Net Income Continuing Discontinued Operations
-3.3-3.4-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Normalized Income
-2.3-3.3-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Interest Income
-000.1-000-0.10.10.10.1
Interest
-------------
Net Interest Income
000.1-000-0.10.10.10.1
EBIT
-2.3-3.3-3.7-3.5-4-2.9-2.7-3.4-3.1-2.8-2.5-2.2-2.7
EBITDA
-2.3-3.3-3.7-3.5-4-2.9-2.7-3.4-3.1-2.8-2.5-2.2-2.7
Reconciled Cost Of Rev.
-------------
Reconciled Depr.
Profit From Continuing Operations
-3.3-3.4-3.4-3.4-3.9-2.8-2.7-3.4-3-2.7-2.4-2.1-2.6
Normalized EBITDA
-1.4-3.3-3.7-3.5-4-2.9-2.7-3.4-3.1-2.8-2.5-2.2-2.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Processa Pharma Inc competitor comparison and performance snapshot within industry

Processa Pharma Inc annual results: revenue, profit, P&L, and margins as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEUTRAL

    Annual Revenue Processa Pharma Inc Annual Revenue is $0 Million which is growth of 0% YoY.

  • NEGATIVE

    Annual Net Profit Processa Pharma Inc Annual Net Profit is $-14 Million which is growth of -14.5% YoY.

Processa Pharmaceuticals Inc, Earnings Report - Annual Results, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsTTMDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
 0.1
Cost Of Rev. Ann.
-
-
 ---------0.1
Gross Profit Ann.
-
-
 ---------0-0
Operating Exp. Ann.
-11.6%
16.9%
12.91412.111.520.311.66.43.94.51.80.11
Operating Profit Ann.
-
-
-12.9-14-12.1-11.5-20.3-11.6-6.4-3.9-4.5-1.8-0.1-1
⌄
0%
-
0.10.10.20.30.10-0.3-0-0.1-0.1-0.3-0.2
Other Exp. Ann.
-
-
 0.3---7.3-0.4-8.7----0-1.8
PBT Ann.
-
-
-13.4-13.6-11.9-11.1-27.4-12-15.4-4-4.7-1.9-0.3-3
Tax Ann.
-
-
 --0.5-1-0.6-0.9-
⌄
-
-
-13.4-13.6-11.9-11.1-27.4-11.4-19-3.9-3.8-1.9-0.4-3.4
Diluted NI Avail to Com Stockholders Ann.
-
-
-13.4-13.6-11.9-11.1-27.4-11.4-19-3.9-3.8-1.9-0.4-3.4
EPS Ann.
-
-
 -10.4-96.8-4,240-850-375-1,270-350-350-210-844.2-7,566.1
Diluted EPS Ann.
-
-
 -10.4-96.8-4,240-850-375-1,270-350-350-210-844.2-7,566.1
Number Of Shares End
-
-
 2.60.10.1000000
Total Exp. Ann.
-11.6%
16.9%
 1412.111.520.311.66.43.94.51.80.11.1
Net Income Continuing Discontinued Operations Ann.
-
-
-13.4-13.6-11.9-11.1-27.4-11.4-14.4-3.4-3.8-1.9-0.3-3.4
Normalized Income Ann.
-
-
-12.5-13.9-11.9-11.1-20.2-11-6.3-3.4-3.8-1.9-0.3-1.9
Interest Income Ann.
0%
-
 0.10.20.30.10000
Interest Ann.
-
-
 ----0.300.200.30.2
EBITDA Ann.
-
-
-12.9-14-12.1-11.5-19.5-11.2-14.3-3.1-3.9-1.8-0.1-2.5
Reconciled Cost Of Rev. Ann.
-
-
 ---------0.1
Reconciled Depr. Ann.
-
-
00.80.80.80.80.60.2
Profit From Continuing Operations Ann.
-
-
-13.4-13.6-11.9-11.1-27.4-11.4-14.4-3.4-3.8-1.9-0.3-3
Normalized EBITDA Ann.
-
-
-11.9-14.3-12.1-11.5-12.2-10.8-5.6-3.1-3.9-1.8-0.1-0.7
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Operating Exp. Ann.
1Y CHG
15.7%
2Y CAGR
10.3%
3Y CAGR
-11.6%
5Y CAGR
16.9%
7Y CAGR
17.6%
10Y CAGR
30.2%
Operating Expenses Annual Cr growth is stable compared to historical averages.

Processa Pharma Inc balance sheet as of Dec 2025: assets, liabilities, reserves, and borrowings – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • POSITIVE

    Total Shareholders Fund Processa Pharma Inc Dec-2025 Total Shareholders Fund is $6 Million which is growth of 228.8% YoY.

  • POSITIVE

    Total Assets Processa Pharma Inc Dec-2025 Total Assets is $8 Million which is growth of 142.0% YoY.

Processa Pharmaceuticals Inc, Balance Sheet, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-3.2%
-20.9%
7.83.25.88.626.525.210.913.230.1
⌄
22.4%
-0.9%
2.21.50.81.212.32.93.52.62.42.1
⌄
-9.3%
-24.5%
5.61.757.525.522.989.70.4-2.4-2
Total Capitalization Ann.
-9.3%
-24.6%
5.61.757.525.52389.70.4-2.4-2
Tangible Assets Ann.
-9.3%
-16.9%
5.61.757.517.414.1-1.6-0.70.4-2.4-2
Working Capital Ann.
-22.8%
-25.7%
3.40.34.97.417.415-0.21.40.4-2.4-2
Invested Capital Ann.
-9.3%
-24.7%
5.61.757.525.523.18.89.92.8-0.7-0.6
Tangible Book Value Ann.
-9.3%
-16.9%
5.61.757.517.414.1-1.6-0.70.4-2.4-2
Borrowings Ann.
0%
-36.9%
0.10.20.20.10.310.22.51.61.4
Net Debt Ann.
-
-
------0.1--1.61.4
Share Issued Ann.
-
-
2.60.20.1000000
Number Of Shares End
-
-
2.60.10.1000000
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Total Assets Ann.
1Y CHG
143.8%
2Y CAGR
16%
3Y CAGR
-3.2%
5Y CAGR
-20.9%
7Y CAGR
-7.2%
10Y CAGR
54.6%
Total Assets Annual growth is higher than historical averages.
Total Current Liabilities Ann.
1Y CHG
46.7%
2Y CAGR
77.3%
3Y CAGR
30.1%
5Y CAGR
12.9%
7Y CAGR
17.8%
10Y CAGR
0.5%
Total Current Liabilities Annual Cr growth is higher than historical averages.
Total ShareHolders Funds Ann.
1Y CHG
229.4%
2Y CAGR
5.8%
3Y CAGR
-9.3%
5Y CAGR
-24.5%
7Y CAGR
-7.5%
Total ShareHolders Funds Annual growth is higher than historical averages.

Processa Pharma Inc ROE, ROCE, book value, and debt-to-equity ratio as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Book Value Per Share Processa Pharma Inc Book Value Per Share is $-0 which is growth of -104.2% YoY.

  • NEUTRAL

    ROE Processa Pharma Inc ROE is 0% which is growth of 0% YoY.

Processa Pharmaceuticals Inc, Ratios, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
RoA Ann. %
-
-
--262.87%-154.40%-156.34%-44.23%-105.49%-32.08%-46.49%-124.33%-704.81%-256.74%
ROE Ann. %
-
-
--354.51%-178.52%-166.43%-47.20%-123.03%-43.64%-74.75%---
ROIC %
-
-
--97.9-39.6-103.8-12.1-93.6-14.1-5.9-63.7--
OPM Ann. %
-
-
----------1,430.60%-870.28%
Inventory Turnover Ratio Ann.
-
-
----------1.1
Asset Turnover Ann. %
-
-
---------0.10.1
Working Capital Turnover Ann.
-
-
-0.1
Quick Ratio Ann.
-
-
-0.86.46.517.112.80.62.71.1
Current Ratio Ann.
-
-
-1.27.78.418.913.30.93.11.10.1
Interest Coverage Ratio Ann.
-
-
-----33,032.6-53.8-107-28-51-0.4-11.7
LT Debt To Equity Ann.
-
-
-0000----
*All financials are in USD Million and price data in USD
Add metric to table
Search...

Processa Pharma Inc cash flow: net, operating, investing, and financing flows as of Dec 2025 – 11 year history

Nested row level
Base Level
Reporting Type
Originally Reported
Cell Data
Actual
Table Settings
YoY & New to Old
CAGR Columns
Select...
Nested row level
Base Level
Export
  • NEGATIVE

    Cash From Operating Activity Processa Pharma Inc Cash From Operating Activity is $-11 Million which is growth of -1.2% YoY.

  • POSITIVE

    Net Cash Flow Processa Pharma Inc Net Cash Flow is $4 Million which is growth of 223.6% YoY.

Processa Pharmaceuticals Inc, Cash Flow, standalone, All financials are in USD Million and price data in USD
IndicatorGraphCAGR 3 YrsCAGR 5 YrsDec '25Dec '24Dec '23Dec '22Dec '21Dec '20Dec '19Dec '18Dec '17Dec '16Dec '15
⌄
-
-
-11.4-11.3-8.1-9.6-8.7-3.1-2.8-3.7-1.7-0-0.6
⌄
-
-
-0.9----0100
⌄
-
-1.5%
16.67.76.3-0.49.817.91.72.62.400.8
Cash Plus Cash Eqv. End Of Year Ann.
-5.4%
-18.6%
5.51.24.76.516.515.40.71.72.90
Net Increase In Cash Plus Cash Eqv.s Ann.
-
-21.4%
4.4-3.5-1.8-101.114.7-1.1-1.11.8-0-0
Cash Plus Cash Eqv. Begin Of Year Ann.
-58.3%
11.4%
1.24.76.516.515.40.71.72.91.100
Income Tax Paid Supplemental Data Ann.
-
-
-
Interest Paid Supplemental Data Ann.
-
-
0-0
Capex Ann.
-
-
-0.9-----0-0-
Issuance Of Capital Stock Ann.
-
-0.6%
16.67.86.310.117.12.9--
Issuance Of Debt Ann.
-
-
----0.90.82.600.8
Repayment Of Debt Ann.
-
-
-0-0--------0
Repurchase Of Capital Stock Ann.
-
-
-0-0-0.4-0.1------
Free Cash Flow Ann.
-
-
-12.2-11.3-8.1-9.6-8.7-3.1-2.8-3.7-1.7-0-0.9
*All financials are in USD Million and price data in USD
Add metric to table
Search...
Cash from Financing Act. Ann.
1Y CHG
115.6%
2Y CAGR
62.3%
5Y CAGR
-1.5%
7Y CAGR
30.3%
10Y CAGR
35.4%
Cash from Financing Annual Activity growth is stable compared to historical averages.
×